ArteraAI key facts
as of Oct 2026- Developer of AI-enabled predictive and prognostic cancer tests designed to identify patients who will benefit from therapy intensification.
- ArteraAI is valued at approximately $400.0M as of Oct 2026 (last reported valuation).
- It has raised $109.5M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Coatue Management, Breyer Capital, EDBI, Jeff Dean, Johnson & Johnson JJDC — 30 tracked in total.
- Status: Privately Held (backing).
ArteraAI's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·The complete investor list: 30 names
- ·Watch ArteraAI: the Monday email on marks, rounds and moves
ArteraAI funding rounds
No funding rounds for ArteraAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ArteraAI
30+ArteraAI valuation
ArteraAI's last reported valuation was $400 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
ArteraAI investors
30 investors are on record for ArteraAI, including Coatue Management, Breyer Capital, EDBI and Jeff Dean. By type, the record holds 7 venture capital firms and 1 private equity firm.
About ArteraAI
Developer of AI-enabled predictive and prognostic cancer tests designed to identify patients who will benefit from therapy intensification. The company's tests leverage an algorithm that assesses digital images from a patient's biopsy and learns from a patient's clinical data, enabling clinicians with more information to make informed treatment decisions.
- Sector
- Healthcare
- HQ
- Los Altos, CA, United States
- Founded
- 2021
- Employees
- 136
- Website
- artera.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.